A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

A Phase 1, Single-center, Open-label, Sequential Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

This study is designed to assess the effect of BMS-986196 on the drug levels of caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin in healthy participants.

Inclusion Criteria:

• Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations.
• Body mass index of 18.0 to 33.0 kilogram per meter squared (kg/m^2), inclusive, and body weight ≥50.0 kg.

Exclusion Criteria:

• History of rhabdomyolysis.
• History of peptic ulcer disease or significant GI bleeding.
• History of malignancy in the 5 years prior to screening (except fully excised basal cell carcinoma).